Lead 2

About Tafalgie Therapeutics

Tafalgie Therapeutics is a French biotech developing first-in-class, non-opioid analgesics targeting a significant unmet need in pain management. Its platform leverages the TAFA4 protein, discovered by co-founder Dr. Aziz Moqrich, which modulates pain signals between the peripheral and central nervous systems. The company has advanced its lead candidate, TT5, into Phase 1 clinical trials (TAFAFIRST study) and has demonstrated preclinical efficacy equivalent to morphine without associated adverse effects. As a private, pre-revenue entity, Tafalgie aims to become a leader in pain therapeutics through internal development and strategic partnerships.

Therapeutic Areas